A Phase II Stratified Trial to Assess Haploidentical T-depleted Stem Cell Transplantation in Patients With Sickle Cell Disease With no Available Sibling Donor

About the study

HSCT is currently the only curative option for SCD but less than 20% of SCD patients have a MD donor available. So far, all curative approaches beyond a MSD HSCT at young age are non-satisfactory. With the lack of a suitable donor for the vast majority of patients, the major question of this trial is, if a haploidentical αß/CD19+ T-cell depleted HSCT can be a valid alternative to a MSD HSCT. The main challenge in non-malignant diseases is to offer a safe and GvHD-free HSCT without rejection.

Study point of contact

Katharina Kleinschmidt, MD
+49 (0)941 944-2101
[email protected]
Selim Corbacioglu, MD
+49 (0)941 944-2101
[email protected]

Locations

5 Germany sites

Age

1 to 35 Years

Genotypes

hemoglobin SC

Phase

Phase 2

Study type

Interventional

Age

1 Year - 35 Years

Gender

All

Interventions

Other

Compensation

Unknown

participation requirements

Age 1yr to 35yrs
Homozygous hemoglobin S disease or heterozygous hemoglobin SC or S 0/+
Study specific consent given

Preexisting severe or moderate SCD related complications:

Clinically significant neurological event (stroke) or deficit
Silent crisis, neurocognitive deficit
Pathological angio-MRI with TOF Sequence
TCD velocity >200 cm/s at 2 occasions >1 month apart
More than 5 vaso-occlusive crises (VOC) in the past 1 year or more than 20 VOC in a lifetime
Two or more episodes of acute chest syndrome (ACS) in a lifetime or one episode of ACS in the past 24 months
Chronic transfusion requirement or more than 8 transfusions or one exchange transfusion in a lifetime
Transfusion-refractory allo-immunization
More than five SCD-related hospitalizations in a lifetime
Beginning pulmonary hypertension
Osteonecrosis at more than 2 sites
Beginning SCD Nephropathy
Recurrent priapism (>2)

participation restrictions

Karnofsky or Lansky Performance Score < 70% Patients with donor-specific antibodies (DSA) against the potential stem cell donor by either Cell-based crossmatched assays (Complement-dependent cytotoxicity; CDC) or Flow cytometry crossmatch test or Solid-phase immunoassays (SPI) or Modified SPI such as C4d and C1q assays Whichever method the participating center is experienced in. Patients with major AB0 incompatibility defined according to EBMT Handbook, Edition 2019 Tab 23.1.: ABO incompatibility Recipient Donor Major O A O B O AB A AB B AB Cardiac function: Ejection fraction at rest <45.0% on echocardiography or Shortening fraction of <27.0% by echocardiogram or radionuclide scan (MUGA) Patients with > grade II hypertension by Common Toxicity Criteria (CTC)

Renal function:

Estimated creatinine clearance (for patients > 12 years) greater than 50.0 mL/minute
for pediatric patients (> 1 year to 12 years), GFR estimated by the updated Schwartz formula ≥ 90.0 mL/min/1.73 m2. If < 90 mL/min/1.73 m2, renal function must be measured by 24-hour creatinine clearance or nuclear GFR and must be > 70.0 mL/min/1.73 m2 or
Creatinine clearance below threshold defined for stem cell transplantation according to local clinical standard

Pulmonary function:

DLCO >50% (adjusted for hemoglobin), and FVC and FEV1≥50%; children unable to perform for PFTs, O2 saturation <92% on room air. Liver function: Total bilirubin > 2x the upper limit of normal (unless elevated bilirubin is attributed to Gilbert’s Syndrome) and ALT/AST > 2.5x the upper limit of normal.
Chronic active viral hepatitis
Women who are pregnant (positive serum or urine βHCG) or breastfeeding. Note: Women of childbearing potential must have a negative serum pregnancy test at study entry.
Adults of reproductive potential not willing to use an effective method of birth control during study treatment and for at least 12 months thereafter,
History of uncontrolled autoimmune disease or on active treatment
Patient unable to comply with the treatment protocol
Prior autologous or allogeneic hematopoietic stem cell transplant
Vaccination with a live virus vaccine during the trial
HIV infection
Patients with a history of psychiatric illness or a condition which could interfere with their ability to understand the requirements of the study (this includes alcoholism/drug addiction)
Patients unwilling or unable to comply with the protocol or unable to give informed consent.
Concurrent severe or uncontrolled medical disease (e.g. uncontrolled diabetes, congestive heart failure, myocardial infarction within 6 months prior to the study, unstable and uncontrolled hypertension, chronic renal disease, or active uncontrolled infection) which by assessment of the treating physician could compromise participation in the study

Locations

  • Düsseldorf, Germany, University Hospital Duesseldorf, Clinic for Pediatric Oncology, - Hemtaology and Clinical Immunology, 40225 [Not yet recruiting]
  • Heidelberg, Germany, University Hospital Heidelberg, Department of Pediatric Hematology, Oncology and Immunology, 69120 [Recruiting]
  • Regensburg, Germany, University Hospital Regensburg, Dept. of Ped. Hematology, Oncology and Stem Cell Transplantation, 93053 [Recruiting]
  • Tübingen, Germany, University Children's Hospital Tübingen, 72076 [Recruiting]
  • Würzburg, Germany, University Children's Hospital Würzburg, 97080 Würzburg [Recruiting]
Last updated 2021-07-29